Literature DB >> 21389696

Endogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population.

Mansi Dalal1, Richard D Semba, Kai Sun, Candace Crasto, Ravi Varadhan, Stefania Bandinelli, Jeffrey C Fink, Jack M Guralnik, Luigi Ferrucci.   

Abstract

BACKGROUND/AIMS: The relationship of circulating endogenous secretory receptor for advanced glycation end products (esRAGE) and chronic kidney disease (CKD) has not been well characterized. The aim of the study was to determine whether plasma esRAGE is associated with CKD and is predictive of developing CKD in older adults.
METHODS: The relationship between plasma esRAGE and CKD (more than stage 3 of the National Kidney Foundation classification; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) and CKD over 6 years of follow-up was examined in a cross-sectional and prospective study design in 1,016 men and women, ≥65 years, in the InCHIANTI study, a population-based cohort study of aging in Tuscany, Italy.
RESULTS: At enrollment, 158 (15.5%) had CKD. Mean (SD) plasma esRAGE was 0.45 (0.24) ng/ml. Plasma esRAGE (ng/ml) was associated with CKD (odds ratio per 1 SD = 1.30; 95% CI 1.1-1.6; p < 0.005) in a multivariable logistic regression model, adjusting for potential confounders. Plasma esRAGE was an independent predictor of incident CKD over 6 years of follow-up (hazard ratio per 1 SD = 1.37; 95% CI 1.1-1.7; p < 0.008) in a multivariable Cox proportional hazards model, adjusting for potential confounders.
CONCLUSIONS: Elevated plasma esRAGE is independently associated with CKD and is an independent predictor of incident CKD in older community-dwelling adults.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389696      PMCID: PMC3064940          DOI: 10.1159/000324846

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  25 in total

Review 1.  Advanced glycation end products and the kidney.

Authors:  Jürgen M Bohlender; Sybille Franke; Günter Stein; Gunter Wolf
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 2.  Chronic kidney disease.

Authors:  Eleanor Lederer; Rosemary Ouseph
Journal:  Am J Kidney Dis       Date:  2007-01       Impact factor: 8.860

3.  Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

Authors:  Sho-ichi Yamagishi; Hisashi Adachi; Kazuo Nakamura; Takanori Matsui; Yuko Jinnouchi; Katsuhiko Takenaka; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yoshiyuki Shigeto; Tsutomu Imaizumi
Journal:  Metabolism       Date:  2006-09       Impact factor: 8.694

4.  Soluble receptor for advanced glycation end products in patients with decreased renal function.

Authors:  Marta Kalousová; Magdaléna Hodková; Markéta Kazderová; Jana Fialová; Vladimír Tesar; Sylvie Dusilová-Sulková; Tomás Zima
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

Review 5.  Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.

Authors:  David Stern; Shi Du Yan; Shi Fang Yan; Ann Marie Schmidt
Journal:  Adv Drug Deliv Rev       Date:  2002-12-07       Impact factor: 15.470

6.  Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.

Authors:  Ayumu Nakashima; Juan Jesús Carrero; Abdul Rashid Qureshi; Tetsu Miyamoto; Björn Anderstam; Peter Bárány; Olof Heimbürger; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 8.237

7.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients.

Authors:  Xiaohong Zhang; Matthias Frischmann; Rose Kientsch-Engel; Katharina Steinmann; Helga Stopper; Toshimitsu Niwa; Monika Pischetsrieder
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

9.  Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.

Authors:  Hidenori Koyama; Tetsuo Shoji; Shinya Fukumoto; Kayo Shinohara; Takuhito Shoji; Masanori Emoto; Katsuhito Mori; Hideki Tahara; Eiji Ishimura; Ryusuke Kakiya; Tsutomu Tabata; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-02       Impact factor: 8.311

Review 10.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes.

Authors:  Giuseppina Basta; Ann Marie Schmidt; Raffaele De Caterina
Journal:  Cardiovasc Res       Date:  2004-09-01       Impact factor: 10.787

View more
  3 in total

1.  AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.

Authors:  Kailash Prasad; Indu Dhar; Qifeng Zhou; Hamdi Elmoselhi; Muhammad Shoker; Ahmed Shoker
Journal:  Mol Cell Biochem       Date:  2016-10-06       Impact factor: 3.396

Review 2.  Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?

Authors:  Amelia K Fotheringham; Linda A Gallo; Danielle J Borg; Josephine M Forbes
Journal:  Nutrients       Date:  2022-06-28       Impact factor: 6.706

3.  Luteolin alleviates methylglyoxal-induced cytotoxicity in osteoblastic MC3T3-E1 cells.

Authors:  Kwang Sik Suh; Suk Chon; Eun Mi Choi
Journal:  Cytotechnology       Date:  2016-05-24       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.